Myriad Genetics (MYGN) Long-Term Deferred Tax (2010 - 2016)

Myriad Genetics (MYGN) has 7 years of Long-Term Deferred Tax data on file, last reported at $12.7 million in Q2 2016.

• Long-Term Deferred Tax for Q2 2016 came in at $12.7 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was $12.7 million (changed N/A YoY), and the FY2016 annual result was $12.7 million, changed N/A from the prior year.
• Long-Term Deferred Tax eased to $12.7 million in Q2 2016 per MYGN's latest filing, from $13.5 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $30.6 million in Q2 2012 and troughed at $407000.0 in Q1 2015.
• A 5-year average of $21.3 million and a median of $27.0 million in 2012 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2013 and 2014: Long-Term Deferred Tax increased 21.93% in 2013, then tumbled 88.82% in 2014.
• A 5-year view of Long-Term Deferred Tax shows it stood at $24.6 million in 2012, then increased by 21.93% to $30.0 million in 2013, then sank by 89.33% to $3.2 million in 2014, then jumped by 321.88% to $13.5 million in 2015, then slipped by 5.93% to $12.7 million in 2016.
• Business Quant data shows MYGN's Long-Term Deferred Tax at $12.7 million in Q2 2016, $13.5 million in Q4 2015, and $407000.0 in Q1 2015.